Faculty Articles

Pharmacist Engagement within a Hepatitis C Ambulatory Care Clinic in the Era of a Treatment Revolution

Publication Title

Journal of the American Pharmacists Association (JAPhA)

Publisher

Elsevier

ISSN

1544-3191

Publication Date

11-1-2016

Keywords

adult, aged, 80 and over, ambulatory care, antiviral agents, female, Florida, hepatitis C, humans, male, mass screening, medication adherence, middle aged, patient care team, pharmaceutical services, pharmacists, professional role, treatment outcome, United States, United States Department of Veterans Affairs

Abstract

Objectives: To describe an innovative hepatitis C virus (HCV) care program and treatment outcomes resulting from pharmacist services.

Setting: Adult ambulatory care HCV clinic within the Miami Veteran Affairs Healthcare System.

Practice description: Pharmacists with limited prescriptive authority are integrated into a medical hepatology care team.

Practice innovation: Pharmacists screen patients with HCV infection for treatment eligibility, counsel patients upon treatment initiation, assess ongoing treatment success and toxicity through patient appointments, telephone calls, and the ordering of pertinent laboratory data, and provide oversight of all patients on HCV therapies. Treatment outcomes are reported to the institutional Antimicrobial Stewardship Program.

Evaluation: Data produced from a continuous quality assurance initiative were utilized. Descriptive statistics were used to present data.

Results: From January 2014 through September 2015 there were 1619 pharmacist encounters for 532 unique patients and 597 screenings (including 578 approvals) were completed by a pharmacist. During this time 555 patients were initiated on at least 1 HCV treatment course, with 565 total treatment courses initiated. As new agents became available for use, fluctuation in regimen selection was seen. The most commonly prescribed medications were sofosbuvir (46%), ledipasvir/sofosbuvir (37%), and simeprevir (33%). Of the 565 HCV treatment courses initiated, 360 were completed, 29 were stopped early during treatment, and 176 were ongoing. Of the 360 completed courses, 249 had sustained virologic response at week 12 results available, of which 225 (90%) achieved treatment success and 24 (10%) relapsed. Of the 29 courses stopped early, 11 were due to poor medication adherence and 8 were due to adverse drug reaction.

Conclusion: Through a structured process employing a scope of practice, pharmacists can extend the capacity of medical hepatology providers and provide pharmacotherapy services to enhance care. Information provided here may serve beneficial to others looking to initiate or expand existing HCV pharmacist services.

DOI

10.1016/j.japh.2016.06.013

Volume

56

Issue

6

First Page

670

Last Page

676

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Link to Full Text
Peer Reviewed

Find in your library

Share

COinS